Challenging resistance mechanisms to therapies for metastatic melanoma.

@article{Tentori2013ChallengingRM,
  title={Challenging resistance mechanisms to therapies for metastatic melanoma.},
  author={Lucio Tentori and Pedro Miguel Lacal and Grazia Graziani},
  journal={Trends in pharmacological sciences},
  year={2013},
  volume={34 12},
  pages={656-66}
}
Melanoma is the most aggressive form of skin cancer and, if spread outside the epidermis, has a dismal prognosis. Before the approval of the anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab and the BRAF inhibitors vemurafenib and dabrafenib, no other agents had demonstrated better results in terms of overall survival than the DNA-methylating compound dacarbazine (or its oral analog temozolomide). However, most patients with metastatic melanoma do not… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
25 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…